Subscribe to RSS
DOI: 10.1055/s-0042-1754349
Treating Recurrent Pleural Disease: A Review of Indications and Technique for Chemical Pleurodesis for the Interventional Radiologist
Abstract
Pleural space diseases such as recurrent pleural effusion and pneumothorax inflict a significant symptomatic burden on patients. Guidelines and studies are available to guide best practices in the setting of refractory effusions, mostly in the setting of malignancy, and recurrent pneumothorax. Less data is available to guide management of refractory transudative effusions. Recurrent pleural effusions can be treated with tunneled pleural catheters or catheter-based pleurodesis. While refractory transudative effusions can benefit from tunneled pleural catheter, this is an area of ongoing research. Regarding recurrent pneumothorax, video-assisted thoracoscopic surgery (VATS) pleurodesis using mechanical or laser/argon beam coagulation is the most effective means of preventing recurrence. Catheter based pleurodesis, a less invasive means of administering chemical sclerosant via percutaneous thoracostomy tube, is only used when surgery is not an option. However, both approaches induce inflammation of the pleural space, resulting in adherence of the parietal and visceral pleura to prevent fluid or air re-accumulation. This article will discuss catheter based chemical pleurodesis geared toward the interventional radiologist, including a review of disease processes and indications, technique, and strategies to mitigate complications as well as a literature review comparing percutaneous chemical pleurodesis to other therapies.
Keywords
talc pleurodesis - tunneled pleural catheter - malignant effusion - spontaneous pneumothorax - interventional radiologyPublication History
Article published online:
31 August 2022
© 2022. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Mierzejewski M, Korczynski P, Krenke R, Janssen JP. Chemical pleurodesis - a review of mechanisms involved in pleural space obliteration. Respir Res 2019; 20 (01) 247 DOI: 10.1186/s12931-019-1204-x.
- 2 Miserocchi G. Physiology and pathophysiology of pleural fluid turnover. Eur Respir J 1997; 10 (01) 219-225 DOI: 10.1183/09031936.97.10010219.
- 3 Saguil A, Wyrick K, Hallgren J. Diagnostic approach to pleural effusion. Am Fam Physician 2014; 90 (02) 99-104
- 4 Porcel JM, Light RW. Diagnostic approach to pleural effusion in adults. Am Fam Physician 2006; 73 (07) 1211-1220
- 5 Chaaban T, Kanj N, Bou Akl I. Hepatic Hydrothorax: An Updated Review on a Challenging Disease. Lung 2019; 197 (04) 399-405 DOI: 10.1007/s00408-019-00231-6.
- 6 Freeman RK, Ascioti AJ, Dake M, Mahidhara RS. A propensity-matched comparison of pleurodesis or tunneled pleural catheter for heart failure patients with recurrent pleural effusion. Ann Thorac Surg 2014; 97 (06) 1872-1876 , discussion 1876–1877 DOI: 10.1016/j.athoracsur.2014.02.027.
- 7 Glazer M, Berkman N, Lafair JS, Kramer MR. Successful talc slurry pleurodesis in patients with nonmalignant pleural effusion. Chest 2000; 117 (05) 1404-1409 DOI: 10.1378/chest.117.5.1404.
- 8 Hou F, Qi X, Guo X. Effectiveness and Safety of Pleurodesis for Hepatic Hydrothorax: A Systematic Review and Meta-Analysis. Dig Dis Sci 2016; 61 (11) 3321-3334 DOI: 10.1007/s10620-016-4260-9.
- 9 Milanez de Campos JR, Filho LO, de Campos Werebe E. et al. Thoracoscopy and talc poudrage in the management of hepatic hydrothorax. Chest 2000; 118 (01) 13-17 DOI: 10.1378/chest.118.1.13.
- 10 Majid A, Kheir F, Fashjian M. et al. Tunneled Pleural Catheter Placement with and without Talc Poudrage for Treatment of Pleural Effusions Due to Congestive Heart Failure. Ann Am Thorac Soc 2016; 13 (02) 212-216 DOI: 10.1513/AnnalsATS.201507-471BC.
- 11 Srour N, Potechin R, Amjadi K. Use of indwelling pleural catheters for cardiogenic pleural effusions. Chest 2013; 144 (05) 1603-1608 DOI: 10.1378/chest.13-0331.
- 12 Tremblay A, Mason C, Michaud G. Use of tunnelled catheters for malignant pleural effusions in patients fit for pleurodesis. Eur Respir J 2007; 30 (04) 759-762 DOI: 10.1183/09031936.00164706.
- 13 Chalhoub M, Saqib A, Castellano M. Indwelling pleural catheters: complications and management strategies. J Thorac Dis 2018; 10 (07) 4659-4666 DOI: 10.21037/jtd.2018.04.160.
- 14 Chambers DM, Abaid B, Gauhar U. Indwelling Pleural Catheters for Nonmalignant Effusions: Evidence-Based Answers to Clinical Concerns. Am J Med Sci 2017; 354 (03) 230-235 DOI: 10.1016/j.amjms.2017.03.003.
- 15 Light RW. Clinical practice. Pleural effusion. N Engl J Med 2002; 346 (25) 1971-1977 DOI: 10.1056/NEJMcp010731.
- 16 Sahn SA. Diagnosis and management of parapneumonic effusions and empyema. Clin Infect Dis 2007; 45 (11) 1480-1486 DOI: 10.1086/522996.
- 17 Feller-Kopman DJ, Reddy CB, DeCamp MM. et al. Management of Malignant Pleural Effusions. An Official ATS/STS/STR Clinical Practice Guideline. Am J Respir Crit Care Med 2018; 198 (07) 839-849 DOI: 10.1164/rccm.201807-1415ST.
- 18 Herrera Lara S, Fernández-Fabrellas E, Juan Samper G. et al. Predicting Malignant and Paramalignant Pleural Effusions by Combining Clinical, Radiological and Pleural Fluid Analytical Parameters. Lung 2017; 195 (05) 653-660 DOI: 10.1007/s00408-017-0032-3.
- 19 Thomas JM, Musani AI. Malignant pleural effusions: a review. Clin Chest Med 2013; 34 (03) 459-471 DOI: 10.1016/j.ccm.2013.05.004.
- 20 Taghizadeh N, Fortin M, Tremblay A. US Hospitalizations for Malignant Pleural Effusions: Data From the 2012 National Inpatient Sample. Chest 2017; 151 (04) 845-854 DOI: 10.1016/j.chest.2016.11.010.
- 21 Zamboni MM, da Silva Jr CT, Baretta R, Cunha ET, Cardoso GP. Important prognostic factors for survival in patients with malignant pleural effusion. BMC Pulm Med 2015; 15: 29 DOI: 10.1186/s12890-015-0025-z.
- 22 Porcel JM. Malignant pleural effusions because of lung cancer. Curr Opin Pulm Med 2016; 22 (04) 356-361 DOI: 10.1097/MCP.0000000000000264.
- 23 Sabur NF, Chee A, Stather DR. et al. The impact of tunneled pleural catheters on the quality of life of patients with malignant pleural effusions. Respiration 2013; 85 (01) 36-42 DOI: 10.1159/000342343.
- 24 Bibby AC, Dorn P, Psallidas I. et al. ERS/EACTS statement on the management of malignant pleural effusions. Eur Respir J 2018; 52 (01) 1800349 DOI: 10.1183/13993003.00349-2018.
- 25 Sahn SA. Malignant pleural effusions. Clin Chest Med 1985; 6 (01) 113-125
- 26 Boshuizen RC, Vd Noort V, Burgers JA. et al. A randomized controlled trial comparing indwelling pleural catheters with talc pleurodesis (NVALT-14). Lung Cancer 2017; 108: 9-14 DOI: 10.1016/j.lungcan.2017.01.019.
- 27 Putnam Jr JB, Light RW, Rodriguez RM. et al. A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions. Cancer 1999; 86 (10) 1992-1999
- 28 Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ. BTS Pleural Disease Guideline Group. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010; 65 (Suppl. 02) ii32-ii40 DOI: 10.1136/thx.2010.136994.
- 29 Davies HE, Mishra EK, Kahan BC. et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA 2012; 307 (22) 2383-2389 DOI: 10.1001/jama.2012.5535.
- 30 Wang L, Deng H, Chen X. et al. Talc pleurodesis versus indwelling pleural catheter among patients with malignant pleural effusion: a meta-analysis of randomized controlled trials. World J Surg Oncol 2020; 18 (01) 184 DOI: 10.1186/s12957-020-01940-6.
- 31 Yeung M, Loh EW, Tiong TY, Tam KW. Indwelling pleural catheter versus talc pleurodesis for malignant pleural effusion: a meta-analysis. Clin Exp Metastasis 2020; 37 (04) 541-549 DOI: 10.1007/s10585-020-10042-2.
- 32 Iyer NP, Reddy CB, Wahidi MM. et al. Indwelling Pleural Catheter versus Pleurodesis for Malignant Pleural Effusions. A Systematic Review and Meta-Analysis. Ann Am Thorac Soc 2019; 16 (01) 124-131 DOI: 10.1513/AnnalsATS.201807-495OC.
- 33 Anderson CB, Philpott GW, Ferguson TB. The treatment of malignant pleural effusions. Cancer 1974; 33 (04) 916-922 DOI: 10.1002/1097-0142(197404)33:4<916:aid-cncr2820330405>3.0.co;2-u.
- 34 Petrov D, Mihalova T, Valchev D. Malignant pleural effusions and trapped lung. AME Med J 2020; 5 (00) DOI: 10.21037/amj.2020.02.08.
- 35 Dresler CM, Olak J, Herndon II JE. et al; Cooperative Groups Cancer and Leukemia Group B, Eastern Cooperative Oncology Group, North Central Cooperative Oncology Group, Radiation Therapy Oncology Group. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest 2005; 127 (03) 909-915 DOI: 10.1378/chest.127.3.909.
- 36 Terra RM, Junqueira JJM, Teixeira LR, Vargas FS, Pêgo-Fernandes PM, Jatene FB. Is full postpleurodesis lung expansion a determinant of a successful outcome after talc pleurodesis?. Chest 2009; 136 (02) 361-368 DOI: 10.1378/chest.08-2448.
- 37 Yim AP, Chan AT, Lee TW, Wan IY, Ho JK. Thoracoscopic talc insufflation versus talc slurry for symptomatic malignant pleural effusion. Ann Thorac Surg 1996; 62 (06) 1655-1658
- 38 Bhatnagar R, Piotrowska HEG, Laskawiec-Szkonter M. et al. Effect of Thoracoscopic Talc Poudrage vs Talc Slurry via Chest Tube on Pleurodesis Failure Rate Among Patients With Malignant Pleural Effusions: A Randomized Clinical Trial. JAMA 2020; 323 (01) 60-69 DOI: 10.1001/jama.2019.19997.
- 39 Kuzdzał J, Sładek K, Wasowski D. et al. Talc powder vs doxycycline in the control of malignant pleural effusion: a prospective, randomized trial. Med Sci Monit 2003; 9 (06) PI54-PI59
- 40 Hsia D, Musani AI. Management options for the complicated pleural space. Curr Respir Care Rep 2013; 2 (02) 109-117 DOI: 10.1007/s13665-013-0044-2.
- 41 Stodghill JD, Collins DT, Mahajan AK, Khandhar SJ. Primary spontaneous pneumothorax: A pathway to practice. AME Med J 2019;4(08). Accessed October 8, 2021: https://amj.amegroups.com/article/view/4806
- 42 Vuong NL, Elshafay A, Thao LP. et al. Efficacy of treatments in primary spontaneous pneumothorax: A systematic review and network meta-analysis of randomized clinical trials. Respir Med 2018; 137: 152-166 DOI: 10.1016/j.rmed.2018.03.009.
- 43 How CH, Hsu HH, Chen JS. Chemical pleurodesis for spontaneous pneumothorax. J Formos Med Assoc 2013; 112 (12) 749-755 DOI: 10.1016/j.jfma.2013.10.016.
- 44 Gupta D, Hansell A, Nichols T, Duong T, Ayres JG, Strachan D. Epidemiology of pneumothorax in England. Thorax 2000; 55 (08) 666-671 DOI: 10.1136/thorax.55.8.666.
- 45 Bobbio A, Dechartres A, Bouam S. et al. Epidemiology of spontaneous pneumothorax: gender-related differences. Thorax 2015; 70 (07) 653-658 DOI: 10.1136/thoraxjnl-2014-206577.
- 46 MacDuff A, Arnold A, Harvey J. BTS Pleural Disease Guideline Group. Management of spontaneous pneumothorax: British Thoracic Society pleural disease guideline 2010. Thorax 2010; 65 (Suppl. 02) ii18-ii31 DOI: 10.1136/thx.2010.136986.
- 47 Baumann MH, Strange C, Heffner JE. et al; AACP Pneumothorax Consensus Group. Management of spontaneous pneumothorax: an American College of Chest Physicians Delphi consensus statement. Chest 2001; 119 (02) 590-602 DOI: 10.1378/chest.119.2.590.
- 48 Walker SP, Bibby AC, Halford P, Stadon L, White P, Maskell NA. Recurrence rates in primary spontaneous pneumothorax: a systematic review and meta-analysis. Eur Respir J 2018; 52 (03) 1800864 DOI: 10.1183/13993003.00864-2018.
- 49 Alayouty HD, Hasan TM, Alhadad ZA, Omar Barabba R. Mechanical versus chemical pleurodesis for management of primary spontaneous pneumothorax evaluated with thoracic echography. Interact Cardiovasc Thorac Surg 2011; 13 (05) 475-479 DOI: 10.1510/icvts.2011.270280.
- 50 Joshi V, Kirmani B, Zacharias J. Thoracotomy versus VATS: is there an optimal approach to treating pneumothorax?. Ann R Coll Surg Engl 2013; 95 (01) 61-64 DOI: 10.1308/003588413X13511609956138.
- 51 Hallifax RJ, Yousuf A, Jones HE, Corcoran JP, Psallidas I, Rahman NM. Effectiveness of chemical pleurodesis in spontaneous pneumothorax recurrence prevention: a systematic review. Thorax 2017; 72 (12) 1121-1131 DOI: 10.1136/thoraxjnl-2015-207967.
- 52 Barker A, Maratos EC, Edmonds L, Lim E. Recurrence rates of video-assisted thoracoscopic versus open surgery in the prevention of recurrent pneumothoraces: a systematic review of randomised and non-randomised trials. Lancet 2007; 370 (9584): 329-335 DOI: 10.1016/S0140-6736(07)61163-5.
- 53 Heffner JE, Huggins JT. Management of secondary spontaneous pneumothorax: there's confusion in the air. Chest 2004; 125 (04) 1190-1192 DOI: 10.1378/chest.125.4.1190.
- 54 Xia H, Wang XJ, Zhou Q, Shi HZ, Tong ZH. Efficacy and safety of talc pleurodesis for malignant pleural effusion: a meta-analysis. PLoS One 2014; 9 (01) e87060 DOI: 10.1371/journal.pone.0087060.
- 55 Beltsios ET, Mavrovounis G, Adamou A, Panagiotopoulos N. Talc pleurodesis in malignant pleural effusion: a systematic review and meta-analysis. Gen Thorac Cardiovasc Surg 2021; 69 (05) 832-842 DOI: 10.1007/s11748-020-01549-2.
- 56 Zimmer PW, Hill M, Casey K, Harvey E, Low DE. Prospective randomized trial of talc slurry vs bleomycin in pleurodesis for symptomatic malignant pleural effusions. Chest 1997; 112 (02) 430-434 DOI: 10.1378/chest.112.2.430.
- 57 Light RW, O'Hara VS, Moritz TE. et al. Intrapleural tetracycline for the prevention of recurrent spontaneous pneumothorax. Results of a Department of Veterans Affairs cooperative study. JAMA 1990; 264 (17) 2224-2230
- 58 Hurewitz AN, Lidonicci K, Wu CL, Reim D, Zucker S. Histologic changes of doxycycline pleurodesis in rabbits. Effect of concentration and pH. Chest 1994; 106 (04) 1241-1245 DOI: 10.1378/chest.106.4.1241.
- 59 Vargas FS, Wang NS, Lee HM, Gruer SE, Sassoon CS, Light RW. Effectiveness of bleomycin in comparison to tetracycline as pleural sclerosing agent in rabbits. Chest 1993; 104 (05) 1582-1584 DOI: 10.1378/chest.104.5.1582.
- 60 Wooten SA, Barbarash RA, Strange C, Sahn SA. Systemic absorption of tetracycline and lidocaine following intrapleural instillation. Chest 1988; 94 (05) 960-963 DOI: 10.1378/chest.94.5.960.
- 61 Smythe WR, Bavaria JE. Tetracycline pleurodesis–associated acute renal failure. Chest 1993; 104 (04) 1274-1276 DOI: 10.1378/chest.104.4.1274.
- 62 Robinson LA, Fleming WH, Galbraith TA. Intrapleural doxycycline control of malignant pleural effusions. Ann Thorac Surg 1993; 55 (05) 1115-1121 , discussion 1121–1122 DOI: 10.1016/0003-4975(93)90017-c.
- 63 Song KS, Keum D, Kim JB. Chemical Pleurodesis Using Doxycycline and Viscum album Extract. Korean J Thorac Cardiovasc Surg 2017; 50 (04) 281-286 DOI: 10.5090/kjtcs.2017.50.4.281.
- 64 Mitchem RE, Herndon BL, Fiorella RM, Molteni A, Battie CN, Reisz GR. Pleurodesis by autologous blood, doxycycline, and talc in a rabbit model. Ann Thorac Surg 1999; 67 (04) 917-921 DOI: 10.1016/s0003-4975(99)00160-5.
- 65 Matin TN, Gleeson FV. Interventional radiology of pleural diseases. Respirology 2011; 16 (03) 419-429 DOI: 10.1111/j.1440-1843.2011.01948.x.
- 66 Kandarpa K, Machan L, Durham J. Handbook of Interventional Radiologic Procedures. Lippincott Williams & Wilkins; 2016
- 67 Corcoran JP, Hallifax RJ, Mercer RM. et al. Thoracic Ultrasound as an Early Predictor of Pleurodesis Success in Malignant Pleural Effusion. Chest 2018; 154 (05) 1115-1120 DOI: 10.1016/j.chest.2018.08.1031.
- 68 Feller-Kopman D, Berkowitz D, Boiselle P, Ernst A. Large-volume thoracentesis and the risk of reexpansion pulmonary edema. Ann Thorac Surg 2007; 84 (05) 1656-1661 DOI: 10.1016/j.athoracsur.2007.06.038.
- 69 Grogan DR, Irwin RS, Channick R. et al. Complications associated with thoracentesis. A prospective, randomized study comparing three different methods. Arch Intern Med 1990; 150 (04) 873-877 DOI: 10.1001/archinte.150.4.873.
- 70 Miller KS, Sahn SA. Chest tubes. Indications, technique, management and complications. Chest 1987; 91 (02) 258-264 DOI: 10.1378/chest.91.2.258.
- 71 Mercaldi CJ, Lanes SF. Ultrasound guidance decreases complications and improves the cost of care among patients undergoing thoracentesis and paracentesis. Chest 2013; 143 (02) 532-538 DOI: 10.1378/chest.12-0447.
- 72 Ahmed O, Zangan S. Emergent management of empyema. Semin Intervent Radiol 2012; 29 (03) 226-230 DOI: 10.1055/s-0032-1326933.
- 73 Valji K. The Practice of Interventional Radiology, with Online Cases and Video E-Book: Expert Consult Premium Edition - Enhanced Online Features. Elsevier Health Sciences; 2011
- 74 Thornton RH, Miller Z, Covey AM. et al. Tunneled pleural catheters for treatment of recurrent malignant pleural effusion following failed pleurodesis. J Vasc Interv Radiol 2010; 21 (05) 696-700 DOI: 10.1016/j.jvir.2010.01.021.
- 75 Marquette CH, Marx A, Leroy S. et al; Pneumothorax Study Group. Simplified stepwise management of primary spontaneous pneumothorax: a pilot study. Eur Respir J 2006; 27 (03) 470-476 DOI: 10.1183/09031936.06.00104905.
- 76 Watanabe T, Fukai I, Okuda K. et al. Talc pleurodesis for secondary pneumothorax in elderly patients with persistent air leak. J Thorac Dis 2019; 11 (01) 171-176 DOI: 10.21037/jtd.2018.12.85.
- 77 Faiz SA, Pathania P, Song J. et al. Indwelling Pleural Catheters for Patients with Hematologic Malignancies. A 14-Year, Single-Center Experience. Ann Am Thorac Soc 2017; 14 (06) 976-985 DOI: 10.1513/AnnalsATS.201610-785OC.
- 78 Rahman NM, Pepperell J, Rehal S. et al. Effect of Opioids vs NSAIDs and Larger vs Smaller Chest Tube Size on Pain Control and Pleurodesis Efficacy Among Patients With Malignant Pleural Effusion: The TIME1 Randomized Clinical Trial. JAMA 2015; 314 (24) 2641-2653 DOI: 10.1001/jama.2015.16840.
- 79 Hunt I, Teh E, Southon R, Treasure T. Using non-steroidal anti-inflammatory drugs (NSAIDs) following pleurodesis. Interact Cardiovasc Thorac Surg 2007; 6 (01) 102-104 DOI: 10.1510/icvts.2006.140400.
- 80 Fysh ETH, Tremblay A, Feller-Kopman D. et al. Clinical outcomes of indwelling pleural catheter-related pleural infections: an international multicenter study. Chest 2013; 144 (05) 1597-1602 DOI: 10.1378/chest.12-3103.
- 81 Heidecker J, Huggins JT, Sahn SA, Doelken P. Pathophysiology of pneumothorax following ultrasound-guided thoracentesis. Chest 2006; 130 (04) 1173-1184 DOI: 10.1378/chest.130.4.1173.
- 82 Wrightson JM, Fysh E, Maskell NA, Lee YCG. Risk reduction in pleural procedures: sonography, simulation and supervision. Curr Opin Pulm Med 2010; 16 (04) 340-350 DOI: 10.1097/MCP.0b013e32833a233b.
- 83 Tan C, Tien M, Lee CP. Talc pleurodesis: It's not for everyone. Eur Respir J 2016; 48 (Suppl. 60) DOI: 10.1183/13993003.congress-2016.PA3390.
- 84 Brant A, Eaton T. Serious complications with talc slurry pleurodesis. Respirology 2001; 6 (03) 181-185 DOI: 10.1046/j.1440-1843.2001.00327.x.
- 85 Fortin M, Tremblay A. Pleural controversies: indwelling pleural catheter vs. pleurodesis for malignant pleural effusions. J Thorac Dis 2015; 7 (06) 1052-1057 DOI: 10.3978/j.issn.2072-1439.2015.01.51.
- 86 Ukale V, Agrenius V, Widström O, Hassan A, Hillerdal G. Inflammatory parameters after pleurodesis in recurrent malignant pleural effusions and their predictive value. Respir Med 2004; 98 (12) 1166-1172 DOI: 10.1016/j.rmed.2004.04.008.
- 87 Koegelenberg CFN, Shaw JA, Irusen EM, Lee YCG. Contemporary best practice in the management of malignant pleural effusion. Ther Adv Respir Dis 2018; 12: 17 53466618785098 DOI: 10.1177/1753466618785098.
- 88 Janssen JP, Collier G, Astoul P. et al. Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study. Lancet 2007; 369 (9572): 1535-1539 DOI: 10.1016/S0140-6736(07)60708-9.
- 89 Montes-Worboys A, Rodriguez-Portal JA, Arellano-Orden E, Digón-Pereiras J, Rodriguez-Panadero F. Interleukin-8 activates coagulation and correlates with survival after talc pleurodesis. Eur Respir J 2010; 35 (01) 160-166 DOI: 10.1183/09031936.00146808.
- 90 Davies CW, Traill ZC, Gleeson FV, Davies RJ. Intrapleural streptokinase in the management of malignant multiloculated pleural effusions. Chest 1999; 115 (03) 729-733 DOI: 10.1378/chest.115.3.729.